Is Aerie Pharmaceuticals a Buy?
Investors can't fault the ambition of Aerie Pharmaceuticals (NASDAQ: AERI). The company aspires to consolidate a fragmented market for glaucoma treatments and grab a combined 40% market share with its two drug products, Rhopressa and Rocklatan. However, those efforts are off to a frustratingly slow start. The drug duo held a combined 2% market share at the end of 2019.
While it's still relatively early in the trajectory of the franchise, Wall Street has adopted a less than enthusiastic stance on the portfolio. On the one hand, that might be the most realistic approach given the obstacles encountered to date. On the other hand, investors with a long-term mindset might find an opportunity at a sub-$700 million market valuation.
Is this small-cap stock a buy?
Source Fool.com
